JP2015512927A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512927A5
JP2015512927A5 JP2015504987A JP2015504987A JP2015512927A5 JP 2015512927 A5 JP2015512927 A5 JP 2015512927A5 JP 2015504987 A JP2015504987 A JP 2015504987A JP 2015504987 A JP2015504987 A JP 2015504987A JP 2015512927 A5 JP2015512927 A5 JP 2015512927A5
Authority
JP
Japan
Prior art keywords
factor
pharmaceutical composition
blood coagulation
composition according
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015504987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512927A (ja
Filing date
Publication date
Priority claimed from GBGB1206628.8A external-priority patent/GB201206628D0/en
Priority claimed from GBGB1213712.1A external-priority patent/GB201213712D0/en
Priority claimed from GBGB1214985.2A external-priority patent/GB201214985D0/en
Application filed filed Critical
Priority claimed from PCT/EP2013/057928 external-priority patent/WO2013156488A2/en
Publication of JP2015512927A publication Critical patent/JP2015512927A/ja
Publication of JP2015512927A5 publication Critical patent/JP2015512927A5/ja
Pending legal-status Critical Current

Links

JP2015504987A 2012-04-16 2013-04-16 最適化された皮下治療薬 Pending JP2015512927A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1206628.8 2012-04-16
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors
GBGB1213712.1A GB201213712D0 (en) 2012-08-01 2012-08-01 Modified therapeutic agents
GB1213712.1 2012-08-01
GB1214985.2 2012-08-22
GBGB1214985.2A GB201214985D0 (en) 2012-08-22 2012-08-22 Modified therapeutic agents
PCT/EP2013/057928 WO2013156488A2 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017171545A Division JP6550107B2 (ja) 2012-04-16 2017-09-06 最適化された皮下治療薬

Publications (2)

Publication Number Publication Date
JP2015512927A JP2015512927A (ja) 2015-04-30
JP2015512927A5 true JP2015512927A5 (https=) 2016-06-16

Family

ID=48190923

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015504987A Pending JP2015512927A (ja) 2012-04-16 2013-04-16 最適化された皮下治療薬
JP2017171545A Expired - Fee Related JP6550107B2 (ja) 2012-04-16 2017-09-06 最適化された皮下治療薬
JP2019073048A Pending JP2019131593A (ja) 2012-04-16 2019-04-05 最適化された皮下治療薬

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017171545A Expired - Fee Related JP6550107B2 (ja) 2012-04-16 2017-09-06 最適化された皮下治療薬
JP2019073048A Pending JP2019131593A (ja) 2012-04-16 2019-04-05 最適化された皮下治療薬

Country Status (29)

Country Link
US (2) US20150086524A1 (https=)
EP (1) EP2838566A2 (https=)
JP (3) JP2015512927A (https=)
KR (1) KR102137290B1 (https=)
CN (1) CN104411335A (https=)
AP (1) AP2014008049A0 (https=)
AU (3) AU2013248296A1 (https=)
BR (1) BR112014025737A2 (https=)
CA (1) CA2869993C (https=)
CL (1) CL2014002773A1 (https=)
CO (1) CO7151496A2 (https=)
CR (1) CR20140475A (https=)
EA (1) EA033469B1 (https=)
EC (1) ECSP14023048A (https=)
GB (3) GB201910190D0 (https=)
GE (1) GEP201706716B (https=)
HK (1) HK1200695A1 (https=)
IL (1) IL235129B (https=)
IN (1) IN2014DN08598A (https=)
MD (1) MD20140123A2 (https=)
MX (2) MX2014012512A (https=)
MY (1) MY190257A (https=)
NI (1) NI201400122A (https=)
NZ (1) NZ701205A (https=)
PE (1) PE20150226A1 (https=)
PH (1) PH12014502314B1 (https=)
SG (1) SG11201406492YA (https=)
WO (1) WO2013156488A2 (https=)
ZA (1) ZA201407370B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104073482A (zh) * 2013-12-30 2014-10-01 江苏众红生物工程创药研究院有限公司 聚乙二醇化的组织激肽释放酶及其制备方法和应用
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
WO2016198641A1 (en) * 2015-06-12 2016-12-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
CN109998994B (zh) * 2018-02-13 2021-12-07 四川大学 包含药物的柔性脂质体及其制备方法
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
CN115443147A (zh) * 2020-04-23 2022-12-06 伊莱利利公司 抗体的皮下吸收和生物利用度

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (https=) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
AU5858690A (en) * 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
EP0662078B1 (en) 1992-09-28 2003-05-02 Research Corporation Technologies, Inc. Reagents for peptide couplings
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH0892294A (ja) * 1994-09-29 1996-04-09 Teijin Ltd ヒト活性化プロテインｃ誘導体
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CA2177644A1 (en) * 1995-05-31 1996-12-01 Peter D. Senter Polymeric prodrugs for beta-lactamase and uses thereof
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
WO1999043357A1 (en) * 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
EP1280548B1 (en) 2000-05-03 2013-12-11 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor VII
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
UA86744C2 (en) * 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
US20130137157A1 (en) * 2003-04-09 2013-05-30 Novo Nordisk A/S Glycopegylated factor vii and factor viia
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
EP1721610B1 (en) 2004-03-04 2009-05-13 Eisai R&D Management Co., Ltd. Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US20090176967A1 (en) 2004-08-02 2009-07-09 Novo Nordisk Healthcare A/G Conjugation of FVII
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
MX2008002395A (es) * 2005-08-19 2008-03-18 Neose Technologies Inc Factor vii y factor viia glicopegilados.
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
EP2114458B1 (en) * 2006-12-27 2014-02-26 Nektar Therapeutics Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
US20100143326A1 (en) 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
CA2683443A1 (en) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
EP2014299A1 (en) 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
CN101820920B (zh) 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
US8552046B2 (en) 2007-10-16 2013-10-08 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulation factor VIIa modulator
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
JP2011517950A (ja) * 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
DK2280734T3 (da) * 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
EP2285401A1 (en) * 2008-05-23 2011-02-23 Novo Nordisk Health Care AG Low viscosity compositions comprising a pegylated gla-domain containing protein
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
DK2349341T3 (da) * 2008-10-15 2014-01-06 Baxter Int Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer
US20100099616A1 (en) * 2008-10-17 2010-04-22 Baxter International Inc. Modified blood factors comprising a low degree of water soluble polymer
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
ES2597954T3 (es) * 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP2536753B1 (en) * 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
TR201908836T4 (tr) * 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
WO2012088123A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Polymer-factor vii moiety conjugates

Similar Documents

Publication Publication Date Title
JP2015512927A5 (https=)
Vecsernyés et al. Cyclodextrins, blood–brain barrier, and treatment of neurological diseases
Ibraheem et al. Administration strategies for proteins and peptides
ES2268710T3 (es) Uso de los dipeptidos glu-trp para la elaboracion de un medicamento para el tratamiento de diferentes condiciones que involucran neovasculacion.
MY190257A (en) Optimised subcutaneous therapeutic agents
ES2941640T3 (es) Moduladores de la actividad del complemento
JP5956715B2 (ja) Ｅｔｂ受容体アゴニストを用いた脳卒中または脳血管障害の治療方法
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
RU2010120672A (ru) Доставка активных веществ
JP2011527301A5 (https=)
JP2011518179A5 (https=)
JP2015508771A5 (https=)
JP2024517334A (ja) コロナウイルス疾患（ｃｏｖｉｄ－１９）における急性呼吸窮迫症候群（ａｒｄｓ）の治療のための医薬組成物及び方法
JP2023531679A5 (https=)
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
AU2017213440A1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
ES2599659T3 (es) Uso de antagonistas del receptor de la adenosina A2B para el tratamiento de la insuficiencia cardiaca y la arritmia en pacientes después de un infarto de miocardio
JP2012524725A5 (https=)
CN102241735B (zh) 用于预防及治疗急性冠脉综合症及抗凝抗血栓治疗的多肽及其应用
JP2014504601A5 (https=)
US12552848B2 (en) Hydrochloride salts of C5a receptor agonist peptides
RU2290195C1 (ru) Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями
WO2022029810A1 (en) Peptides able to bind angiotensin-converting enzyme 2 (ace2) and medical uses thereof
JP2018534306A5 (https=)